Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
FG New America Acquisition (FGNA.U)
Boqii Holding Limited (BQ)
Orphazyme A/S (ORPH)
Palantir Technologies Inc. (PLTR)
Yalla Group Limited (YALA)
Recharge Acquisition (RCHGU)
Chindata Group Holdings Limited (CD)
Asana, Inc. (ASAN)
Lixiang Education Holding Co., Ltd. (LXEH)
Pulmonx Corporation (LUNG)
Mission Produce, Inc. (AVO)
Academy Sports and Outdoors, Inc. (ASO)
Immunome Inc. (IMNM)
Priced IPO
Amesite Operating (AMST)
VIA optronics AG (VIAO)
Prelude Therapeutics Incorporated (PRLD)
Graybug Vision, Inc. (GRAY)
PMV Pharmaceuticals, Inc (PMVP)
Siyata Mobile Inc. (SYAT)
Taysha Gene Therapies, Inc. (TSHA)
Bentley Systems, Inc. (BSY)
Corsair Gaming, Inc. (CRSR)
GoodRx Holdings, Inc. (GDRX)
Laird Superfood, Inc. (LSF)
Unity Software, Inc. (U)
Vitru Limited (VTRU)
Athira Pharma, Inc. (ATHA)
COMPASS Pathways plc (CMPS)
Broadstone Net Lease Inc. (BNL)
Sumo Logic, Inc. (SUMO)
Pactiv Evergreen Inc (PTVE)
American Well Corporation (AMWL)
Dyne Therapeutics Inc (DYN)
More companies

Ayala Pharmaceuticals, Inc. (AYLA)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Their differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of their bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. Their current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Gamma secretase is the enzyme responsible for Notch activation and, when inhibited, turns off the Notch pathway activation. Aberrant activation of the Notch pathway has long been implicated in multiple solid tumor and hematological cancers and has often been associated with more aggressive cancers. In cancers, Notch is known to serve as a critical facilitator in processes such as cellular proliferation, survival, migration, invasion, drug resistance and metastatic spread, all of which contribute to a poorer patient prognosis. AL101 and AL102 are designed to address the underlying key drivers of tumor growth, and their initial Phase 2 clinical data of AL101 suggest that their approach may address the shortcomings of existing treatment options. They believe that their novel product candidates, if approved, have the potential to transform treatment outcomes for patients suffering from rare and aggressive cancers.
Industry
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
CEO CFO
Roni Mamluk Yossi Maimon
Employees Founded
29 2017

Contacts

Address: Oppenheimer 4, Rehovot 7670104, Israel

Telephone: +972-8-373-1541

Web page: http://www.ayalapharma.com

IPO information

Expected Date 5/8/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $181.7
Revenues (MM) $2.3
Net Income (Loss) (MM) $-17.8

Voting

What do you think will happen with the AYLA share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 3.3
Shares Revised (MM) 3.7
Expected offer amount (MM) $55
Realized offer amount(MM) $55.5
Underwriters
Citigroup/ Jefferies
CO-Managers
Oppenheimer/ Raymond James

Sector: Healthcare

Tweets about $AYLA

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats